NV 50Alternative Names: NV50
Latest Information Update: 04 Mar 2008
At a glance
- Originator Novogen
- Mechanism of Action Estrogen receptor antagonists; Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 04 Mar 2008 Discontinued - Preclinical for Breast cancer in Australia (unspecified route)
- 24 Apr 2007 No development reported - Preclinical for Breast cancer in Australia (unspecified route)
- 12 Nov 2001 New profile